The prospect of Xihuang pill in the treatment of cancers

Zehui Chen; Zhiming Li; Shuo Yang; Yue Wei; Jing An

doi:10.1016/j.heliyon.2023.e15490

The prospect of Xihuang pill in the treatment of cancers

Heliyon. 2023 Apr 14;9(4):e15490. doi: 10.1016/j.heliyon.2023.e15490. eCollection 2023 Apr.

Authors

Zehui Chen¹, Zhiming Li², Shuo Yang¹, Yue Wei², Jing An²

Affiliations

¹ Institute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
² The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, 100029, China.

Abstract

Background: Xihuang pill, a Traditional Chinese Medicine (TCM) prescription and a representative of Huoxuehuayu therapy (one of the TCM therapies to promote blood circulation and remove blood stasis), has been widely used in breast cancer treatments. Although some evidence suggests the efficacy and safety of the Xihuang pill in treating certain cancer, the overall efficacy of the Xihuang pill in other cancer treatment is uncertain.

Objective: This study aimed to summarize the current clinical literature and provided evidence support for addressing the research question of whether the Xihuang pill is safe and effective in the treatment of various cancers as Huoxuehuayu therapy, and possibly identify the clinical dosage range and therapeutic effect of Xihuang pills.

Method: Seven Chinese and English databases such as PubMed, CNKI, and Google Scholar were searched to collect the publications on Xihuang pill and cancer. Then the researchers extracted data from the articles that met the inclusion criteria and used SAS statistical program version 9.4 (by SAS Institute, Cary, North Carolina, USA) for statistical statistics.

Results: Our search identified 78 studies, including 69 RCTs (randomized control trials), 6 NRCCs (non-randomized concurrent control trials), and 3 BAS (before-after study), evaluating 3151 patients in total. The daily doses of Xihuang pills/capsule were between 2 g and 60 g, and duration between 2 weeks and 5 years, mostly used in the middle or late stage of cancer. The therapeutic effect of the Xihuang pill was mainly reflected in improving Complete Response (CR, a term from The Response Evaluation Criteria In Solid Tumors) or Partial Response (PR, a term from The Response Evaluation Criteria In Solid Tumors), reducing adverse reactions, promoting quality of life (QoL), regulating immunity, alleviating pain, prolonging survival, reducing metastasis and recurrence, reducing inflammation, regulating estrogen levels, decreasing hypercoagulative status, and reducing tumor markers.

Conclusion: Xihuang pill representing Huoxuehuayu therapy has a good prospect in the treatment of cancer.

Keywords: Cancer; Huoxuehuayu therapy; Safety and effectiveness; Traditional Chinese medicine; Xihuang pill.